DNA vaccine against feline immunodeficiency virus

Abstract

The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.

Description

[0001] This patent application is a divisional patent application of U.S. Ser. No. 09 / 593,580, filed Jun. 14, 2000, which claims the benefit of priority of U.S. Provisional Serial No. 60 / 138,999, filed Jun. 14, 1999, all of which are incorporated herein by reference.1. FIELD OF THE INVENTION[0002] The present invention is in the field of animal health, and is directed to vaccine compositions and diagnostics for disease. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.2. BACKGROUND OF THE INVENTION[0003] Feline immunodeficiency virus (FIV) infection in cats results in a disease syndrome similar to that caused in humans by human immunodeficiency virus-1 (HIV-1) infection. After infection of cats by FIV, disease progression begins with a transient acute phase illness (8 to 10 weeks), followed by a prolonged asymptomatic phase varying from weeks to years, and a terminal symptomatic ...

AI Technical Summary

Problems solved by technology

In one report, although both cell-mediated and humoral immune responses were induced in cats vaccinated with a multi-epitopic peptide within the ENV protein, vaccination did not confer protection against homologous challenge (Flynn et al., 1997, above).

As in HIV-1, an observation that complicates the development of an effective FIV vaccine is the enhancement of infection that has been observed in cats immunized with certain vaccines.

However, the mechanism by which antibodies enhance FIV infection remains poorly understood.

The enhanced infectivity may interfere with the induction of protective immunity in FIV , which may partially explain the reason why a large number of FIV vaccination experiments in which ENV protein or its subunits were used as vaccines were unsuccessful.

Three different groups have attempted to vaccinate cats with fixed virus-infected cells; however, conflicting results were obtained from these vaccination trials.

The protection conferred by this vaccine, however, was relatively short-lived and difficult to boost (Matteucci et al., 1997, J. Virol. 71:8368-8376).

However, when cats were monitored up to week 50 post-challenge, a loss of protection against the homologous virus was observed.

However, in contrast to the studies described above, vaccination of cats with whole, inactivated FIV incorporated into immune stimulating complexes (ISCOMs) failed to protect against homologous challenge (Hosie et al., 1992, above).

Unfortunately, although significant levels of antibodies were generally induced by such vaccinations, all attempts failed to protect vaccinated cats against homologous challenge (Huisman et al., 1998, above; Flynn et al., 1997, above; Tijhaar et al., 1997, above; Osterhaus et al., 1996, above; Verschoor et al., 1996, above; Rigby et al., 1996, above; Lutz et al., 1995, above; Flynn et al., 1995, Immunol.

However, none of the vaccinated cats were protected from homologous challenge (Cuisinier et al., 1997, Vaccine 15:1085-1094).

Images